Intrinsically zirconium-89-labeled manganese oxide nanoparticles for in vivo dual-modality positron emission tomography and magnetic resonance imaging

Yonghua Zhan, Emily B. Ehlerding, Sixiang Shi, Stephen A. Graves, Shreya Goel, Jonathan W. Engle, Jimin Liang, Weibo Cai

Research output: Journal article publicationJournal articleAcademic researchpeer-review

20 Citations (Scopus)


Manganese-based nanoparticles (NPs) have recently attracted much attention in the field of biomedical imaging due to their impressive enhanced T1 contrast ability. Although the reported manganese-based NPs have exhibited good imaging capabilities as contrast agents, it is still urgent to develop novel multifunctional manganese-based imaging probes for future biomedical imaging, especially PET/MRI probes. Herein, we present chelator-free zirconium-89 ( 89 Zr, t1/2 : 78.4 h) labeling of manganese oxide NPs (Mn 3 O 4 @PEG) with ∼78% labeling yield and good stability. Serial positron emission tomography (PET) and magnetic resonance imaging (MRI) studies non-invasively assessed the biodistribution patterns of the NPs and the feasibility of in vivo dual-modality imaging and lymph-node mapping. Since Mn 3 O 4 NPs exhibited desirable properties for enhanced T1 imaging and the simplicity of chelator-free radiolabeling, [ 89 Zr]Mn 3 O 4 @PEG NPs offer a novel, simple, safe and accurate nanoplatforms for future precise cancer imaging and diagnosis.

Original languageEnglish
Pages (from-to)900-909
Number of pages10
JournalJournal of Biomedical Nanotechnology
Issue number5
Publication statusPublished - 1 May 2018
Externally publishedYes


  • Chelator-free
  • Magnetic resonance imaging
  • Manganese oxide nanoparticles
  • Positron emission tomography
  • Zirconium-89

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this